Mylan Inc. completed a 85,000 square foot, three-story, expansion project at its transdermal patch facility, operated by its Mylan Technologies Inc. subsidiary in St. Albans, Vermont
. The 14-month expansion project increased MTI's total operating space to more than 391,000 square feet.
Through Mylan's investment, including funding for expanded research and development capabilities and additional manufacturing and laboratory space, the company is in the process of adding more than 160 new positions to its St. Albans-based workforce.
MTI produces transdermal drug delivery systems, patches that provide medication through the skin and related technologies. Since becoming a part of the Mylan manufacturing network more than 20 years ago, MTI has developed a number of branded and generic transdermal products available to patients in markets around the world, including the U.S., Canada, Europe, Japan, New Zealand and Australia.
Mylan CEO Heather Bresch said: "Mylan's investment in the ongoing growth of our transdermal franchise demonstrates our continued commitment to and confidence in our ability to provide complex generic and interchangeable products and innovative delivery alternatives, such as transdermals. Through this expansion, MTI will continue to play a critical role in the expansion and diversification of Mylan's global product portfolio, especially when it comes to difficult-to-develop and –manufacture products. I would like to thank Governor Shumlin as well as the city of St. Albans for their ongoing support of this project. Importantly, I would also like to recognize Mylan's more than 590 employees in Vermont for their hard work and dedication to our continued success."